Haemonetics: Can Hospital Growth Justify the Plasma Business Stall?

Haemonetics Corp (HAE) reports fiscal Q1 2027 earnings tomorrow, August 6, before the market opens, with analysts expecting $1.07 per share on revenue estimates around $328 million. The central question: can the blood management technology leader sustain its impressive streak of earnings beats—15 consecutive quarters—even as consensus estimates point to a rare year-over-year decline? With the stock trading at $83.60 and analyst price targets implying meaningful upside, this report will test whether HAE's momentum can withstand tougher comparisons and a challenging operating environment.

Part 1: Earnings Preview

Haemonetics Corporation is a global healthcare company specializing in blood and plasma management solutions, serving hospitals, blood banks, and plasma collection centers with products that optimize blood component collection, processing, and safety. The company operates through two primary segments: Plasma and Blood Center, providing critical infrastructure for the global blood supply chain.

Haemonetics reports fiscal Q1 2027 earnings tomorrow, August 6, before the market open. Analysts expect $1.07 per share, with estimates ranging from $1.02 to $1.13 across six analysts. Revenue estimates center around $328 million. The company most recently reported $1.29 per share for fiscal Q4 2026 (March quarter), beating the $1.27 consensus by 1.38%.

Year-over-year, the $1.07 estimate represents a -2.73% decline from the $1.10 reported in the same quarter last year—a notable shift after multiple quarters of growth. This marks the first anticipated year-over-year earnings decline in recent memory, raising questions about whether operational headwinds or tougher comparisons are weighing on near-term profitability.

Three key themes define this earnings story:

Plasma Market Dynamics: The plasma collection market—a core revenue driver—faces volume and pricing pressures as the industry digests capacity additions from recent years. Investors will scrutinize whether HAE's plasma disposables and equipment sales can maintain momentum amid softer end-market demand and competitive dynamics.

Blood Center Stabilization: After years of pandemic-related volatility, hospital blood centers are normalizing procedure volumes. The question is whether HAE's blood center products can capitalize on this stabilization or whether budget constraints and hospital system consolidation limit growth opportunities.

Margin Trajectory: With revenue growth expected around 5% for the full fiscal year but earnings estimates pointing to near-term pressure, operating margin performance will be critical. Analysts are watching whether supply chain normalization and operational efficiency gains can offset any pricing or mix headwinds.

Analyst commentary ahead of the release reflects cautious optimism. The consensus has drifted lower over the past 90 days—from $1.16 to $1.07 for the upcoming quarter—suggesting analysts are tempering expectations as they incorporate recent business trends. However, the full-year fiscal 2027 estimate of $5.21 still implies +5.04% growth, indicating confidence that any near-term softness is temporary rather than structural.

Part 2: Historical Earnings Performance

Haemonetics has delivered an exceptional track record of earnings beats, surpassing consensus estimates in all four of the past four quarters. The surprise margins have been substantial: +8.91% in June 2025, +13.39% in September 2025, +3.15% in December 2025, and +0.78% most recently in March 2026. This consistent outperformance demonstrates management's ability to exceed expectations, though the magnitude of beats has moderated in recent quarters.

The trend shows a clear pattern: HAE tends to beat estimates, but the size of those beats has compressed from double-digit percentages to low single digits. The June 2025 and September 2025 quarters featured particularly strong beats of 8.91% and 13.39%, respectively, while the two most recent quarters saw more modest outperformance of 3.15% and 0.78%. This deceleration suggests either that analysts have adjusted their models to better capture HAE's performance, or that the company's ability to exceed expectations is narrowing as comparisons toughen.

Given this history, investors should expect HAE to beat the $1.07 consensus tomorrow—the company has earned that benefit of the doubt. However, the magnitude of any beat may be smaller than the double-digit surprises seen earlier in 2025, and guidance for the remainder of fiscal 2027 will be just as important as the Q1 result itself.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Haemonetics reports before the market open, meaning Day 0 captures the first full trading session reaction to results, while Day +1 reflects follow-through momentum.

Historical price behavior around earnings reveals extreme volatility, with an average absolute Day 0 move of 12.81% and Day 0 range of 11.37%. The stock has demonstrated wild swings in both directions: a massive +32.31% surge in November 2025 following a strong beat, and a brutal -26.58% plunge in August 2025. More recent reports have been less dramatic but still significant, with moves ranging from -11.58% to +5.85% on Day 0.

Day +1 follow-through has been more muted, averaging 2.85% with a 6.06% range, suggesting most of the price discovery happens in the immediate reaction session. The February 2026 report stands out as an exception, where a Day 0 decline of -11.58% was followed by an additional -5.79% drop on Day +1, indicating sustained selling pressure.

Investors should brace for significant volatility tomorrow morning. While HAE's consistent beat streak suggests upside potential, the stock's history shows it can move violently in either direction—and double-digit percentage swings are well within the historical norm for this name on earnings day.

Part 2.2: Options Market Expected Move

The options market is pricing in an expected move of 0.00% for the August 21 expiration, which appears to be incomplete or unavailable data. Based on historical earnings moves averaging 12.81% on Day 0, investors should expect material volatility that significantly exceeds typical options-implied ranges for this stock.

Part 3: What Analysts Are Saying

Analyst sentiment on Haemonetics is strongly bullish, with a consensus rating of 4.25 out of 5.0—firmly in "Buy" territory. The current breakdown shows 7 Strong Buys, 1 Moderate Buy, and 4 Holds, with zero sell ratings. This distribution reflects broad confidence in HAE's business model and growth trajectory, even as near-term estimates have moderated.

The average price target of $87.36 implies +4.5% upside from the current price of $83.60, though the range of targets is wide: from a low of $62.00 to a high of $104.00. The high-end target suggests some analysts see potential for a 24% rally if execution remains strong and end-market conditions improve.

Sentiment has remained unchanged over the past month, with the same 7-1-4 Strong Buy/Moderate Buy/Hold split persisting. This stability suggests analysts are holding their positions heading into the report rather than making preemptive adjustments. The lack of recent upgrades or downgrades indicates the Street is waiting for tomorrow's results and guidance to reassess their views.

The consensus price target of $87.36 sits modestly above the current price, implying analysts see HAE as fairly valued with some room to run. However, the wide target range—spanning $42 from low to high—reflects meaningful disagreement about the company's near-term trajectory and valuation multiple. Bulls see continued execution and margin expansion driving the stock toward $100+, while bears worry about plasma market headwinds and tougher growth comparisons justifying a more conservative valuation.

Part 4: Technical Picture

Haemonetics enters earnings with strong technical momentum and a bullish setup across multiple timeframes. The Barchart Technical Opinion currently stands at 88% Buy, unchanged from last week but significantly improved from 56% Buy a month ago. This strengthening signal reflects the stock's sustained rally through the summer, with HAE climbing above all major moving averages.

Timeframe Analysis:

• Short-term (100% Buy): Maximum bullish signal indicates powerful near-term momentum heading into the report
• Medium-term (100% Buy): Equally strong reading confirms the uptrend is well-established beyond just short-term trading
• Long-term (50% Buy): Moderate buy signal suggests some caution in the longer-term trend, though still net positive

Trend Characteristics: The Strong and Strengthening trend environment indicates HAE is in a robust uptrend with improving momentum—a supportive technical backdrop for earnings.

The stock is trading above its 10-day ($83.02), 20-day ($80.00), 50-day ($75.90), 100-day ($67.05), and 200-day ($68.17) moving averages, though slightly below the 5-day ($85.23) after a minor pullback. This alignment of moving averages in ascending order defines a classic uptrend structure, with each timeframe providing potential support on any post-earnings weakness.

The technical setup is supportive heading into earnings, with momentum indicators and moving average alignment both pointing higher. However, the stock's tendency for extreme volatility on earnings day—averaging 12.81% moves—means technical levels could be quickly violated in either direction. The 50-day moving average at $75.90 represents the first major support zone if results disappoint, while a beat could propel HAE toward the $90-$95 range where it would test the upper end of analyst price targets. The strengthening technical opinion and bullish timeframe readings suggest the path of least resistance is higher, but tomorrow's results and guidance will ultimately determine whether this momentum continues or reverses.